Global Conjunctivitis Treatment Market Size, Share & Trends Analysis Report By Disease Type, By Drug Class (Anti-allergic, Antiviral, Artificial Tears, and Antibiotics), By Distribution Channel, By Regional Outlook and Forecast, 2023 - 2030
The Global Conjunctivitis Treatment Market size is expected to reach $6.1 billion by 2030, rising at a market growth of 4.7% CAGR during the forecast period.
Environmental allergens, viral infections, and other triggers contribute to a consistent demand for conjunctivitis treatment across the region. Therefore, the Nort America region captured $1,583.6 million revenue in the market in 2022. North America has a thriving pharmaceutical research and development (R&D) sector, with domestic and multinational pharmaceutical companies conducting innovative research in various therapeutic areas. According to Statistics Canada, in 2020, the R&D pharmaceutical sector contributed $15.9 billion to the Canadian economy in GVA, an increase of 5.8% from the $15.0 billion generated in 2019. The sector's direct impacts accounted for slightly less than half of this amount ($7.9 billion), an increase of 4.5% compared to the $7.6 billion produced in 2019. Indirect impacts accounted for 28.3% of the total GVA in 2020 and increased 6.1% to $4.5 billion, while induced impacts advanced 8.7% to $3.5 billion.
Higher healthcare expenditure often translates into improved access to healthcare services, including eye care. Individuals with conjunctivitis are more likely to seek medical attention and receive timely diagnosis and treatment when healthcare services are readily accessible. Increased healthcare spending allows for the adoption and integration of advanced medical technologies in diagnosing and treating conjunctivitis. Advanced diagnostic tools and treatment modalities contribute to more accurate assessments and effective management of the condition. Additionally, Improved awareness about the symptoms of conjunctivitis prompts individuals to seek medical attention at the early stages of the condition. The implementation of treatment in a punctual manner is facilitated by an early diagnosis, which prevents the development of conjunctivitis and mitigates the intensity of symptoms. Healthcare providers and organizations engage in community outreach programs to disseminate information about eye health. These programs may include eye screenings, educational seminars, the distribution of informational materials, and the raising of awareness about conjunctivitis and available treatments. These initiatives often include campaigns that highlight the importance of eye health and prompt individuals to seek appropriate treatment for eye conditions. Therefore, the rising awareness about eye health is driving the growth of the market.
However, the proliferation of antibiotic-resistant bacterial strains may result from the improper or excessive use of antibiotics to treat bacterial conjunctivitis. This means that the effectiveness of commonly used antibiotics diminishes over time, leading to challenges in treating bacterial infections. Antibiotic resistance narrows the range of effective antibiotics available for treating bacterial conjunctivitis. As resistance spreads, fewer viable treatment options may be available, making it difficult to manage infections with traditional antibiotics. Additionally, antibiotic resistance increases the risk of treatment failure. In cases where the causative bacteria are resistant to commonly prescribed antibiotics, the infection may persist, leading to unresolved symptoms and potential complications.
By Disease Analysis
On the basis of disease type, the market is segmented into allergic conjunctivitis, bacterial conjunctivitis, and viral conjunctivitis. The allergic conjunctivitis segment recorded the largest revenue share in the market in 2022. The surge in allergic conjunctivitis cases drives an increased demand for anti-allergic medications in the market. The rising impact of allergic conjunctivitis prompts innovation in drug delivery systems within the market. This includes the development of advanced eye drop formulations, sustained-release technologies, and other delivery methods to enhance the efficacy and duration of anti-allergic medications.
By Drug Class Analysis
Based on drug class, the market is divided into antibiotics, antiviral, anti-allergic, and artificial tears. In 2022, the anti-allergic segment garnered the highest revenue share in the market. Anti-allergic drugs, particularly antihistamines and mast cell stabilizers, are applied to provide symptomatic relief from common allergic conjunctivitis symptoms. These symptoms include itching, redness, tearing, and swelling. Antihistamines, which block the effects of histamine released during an allergic reaction, are a primary application in allergic conjunctivitis. These drugs help alleviate itching and reduce the overall inflammatory response.
By Distribution Channel Analysis
Based on distribution channel, the market is categorized into hospital pharmacy, retail pharmacy, and online pharmacy. The retail pharmacy segment witnessed a noteworthy revenue share in the market in 2022. Retail pharmacies are often conveniently located in community settings, making them easily accessible to patients. This accessibility is crucial for individuals seeking over the counter (OTC) medications or prescription drugs for without the need for a hospital visit. Many cases of conjunctivitis, especially mild and uncomplicated forms, can be managed with over-the-counter medications. Retail pharmacies provide a wide range of OTC eye drops and treatments, allowing individuals to engage in self-care and promptly address mild symptoms without needing a healthcare provider visit.
By Regional Analysis
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the Asia Pacific region generated a substantial revenue share in the market. The Asia Pacific region is characterized by high population density, with a substantial number of people residing in urban and densely populated areas. This population density contributes to a higher prevalence of infectious diseases, including conjunctivitis, leading to an increased demand for treatment. Environmental factors like air pollution, dust, and exposure to allergens are prevalent in many parts of Asia Pacific. These environmental conditions can contribute to conjunctivitis, particularly allergic conjunctivitis, driving the demand for treatments to manage eye-related symptoms.
Recent Strategies Deployed in the Market
- 2022-Dec: Merck & Co., Inc. came into partnership with Astellas Pharma Inc., a pharmaceutical manufacturing company, and Seagen Inc., a biotechnology research company. Through this partnership, Merck & Co., Inc. would provide initial treatment for specific individuals diagnosed with locally advanced or metastatic urothelial cancer.
- 2021-May: Teva Pharmaceutical Industries Ltd. Introduced "250 mg and 500 mg strength generic Erythromycin tablets". The Erythromycin tablets are employed to treat infections caused by particular, susceptible strains of microorganisms in various diseases.
- 2021-Apr: Teva Pharmaceutical Industries Ltd. Introduced "10 mg, 20 mg, 25 mg, 30 mg, 35 mg and 40 mg strength generic version of Absorica®1 (isotretinoin) capsules" in the United States. The products are available for the treatment of severe recalcitrant nodular acne in patients 12 Years of age and older.
- 2020-Oct: GlaxoSmithKline (GSK) plc reported that the European Commission has given its approval for Zejula (niraparib), a PARP inhibitor taken orally once a day. This approval is specifically for its use as a first-line monotherapy maintenance treatment for adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube, or primary peritoneal cancer, who have achieved complete or partial response following platinum-based chemotherapy.
- 2019-Feb: Bausch Health Companies, Inc. took over Eton Pharmaceuticals Inc., a US-based pharmaceutical manufacturing company. Through this acquisition, Bausch Health Companies, Inc. would enhance its business of eye health products.
List of Key Companies Profiled
- Novartis AG
- Gilead Sciences, Inc.
- GlaxoSmithKline PLC
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Boehringer Ingelheim International GmbH
- AbbVie, Inc.
- AFT Pharmaceuticals
- Bausch Health Companies, Inc.
- Teva Pharmaceutical Industries Ltd.
Global Conjunctivitis Treatment Market Report Segmentation
By Disease Type
- Allergic Conjunctivitis
- Viral Conjunctivitis
- Bacterial Conjunctivitis
By Drug Class
- Anti-allergic
- Antiviral
- Artificial Tears
- Antibiotics
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA